TP53 and ovarian cancer: Previous studies have shown the drug is converted to a methylene quinuclidinone (MQ) compound which covalently binds to the p53 core domain [14,15], and synergistic effects with chemotherapy drugs have been observed in preclinical models of ovarian cancer [16].